Page 6 - Agonist News Today

Researchers conducted a retrospective study to determine whether SSRIs with immunomodulatory and antiplatelet properties can decrease the risk of post-acute sequelae of COVID-19 (PASC).

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

Researchers describe the wide range of neurological effects associated with cannabis use.

A new study posted in the pre-print server bioRxiv* aimed to analyze the impact of COVID-19 on platelet proteome and relate the functional responses of platelets and the formation of platelet-neutrophil aggregate in hospitalized COVID-19 patients.

- Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) -- Company recognizes World Narcolepsy Day on September 22nd - BOSTON and LONDON

The WHO provides interim guidelines for the use of the Valneva vaccine.

Inflammatory myopathies can be challenging to treat, but a new study reports encouraging findings for patients with these debilitating conditions. Researchers from Japan have found that a novel member of a class of anti-diabetes drugs could be the key to treating patients with muscle wasting disease.

Stimulator of interferon genes, or STING, helps regulate immune activation. Thus, drugs that activate STING are being tested as a form of cancer immunotherapy and for treating certain infections.

Researchers described a novel protein subunit vaccine comprising the receptor-binding domain (RBD) of ancestral SARS-CoV-2 spike (S) protein, dimerized with an immunoglobulin (Ig)G1-fraction, crystallizable (Fc) domain.

Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which